Dataset Information

Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.

ABSTRACT: A mini-Tn5 insertion into a ciprofloxacin (CIP)-resistant mutant of Vibrio cholerae O1 revealed that overexpression of the vca0421 gene, which encodes a hypothetical protein, in the CIP-resistant mutant carrying a mutation in the quinolone resistance-determining region (QRDR) of the gyrA gene causes sensitization to CIP. We propose a new intrinsic mechanism of resistance to fluoroquinolones due to the inherently reduced expression of the vca0421 gene in V. cholerae O1.

SUBMITTER: Okuda J

PROVIDER: S-EPMC2976169 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.

Okuda Jun J Hayashi Naoki N Wakahara Yuka Y Gotoh Naomasa N

Antimicrobial agents and chemotherapy 20100830 11

A mini-Tn5 insertion into a ciprofloxacin (CIP)-resistant mutant of Vibrio cholerae O1 revealed that overexpression of the vca0421 gene, which encodes a hypothetical protein, in the CIP-resistant mutant carrying a mutation in the quinolone resistance-determining region (QRDR) of the gyrA gene causes sensitization to CIP. We propose a new intrinsic mechanism of resistance to fluoroquinolones due to the inherently reduced expression of the vca0421 gene in V. cholerae O1. ...[more]

PMID: 20805389

Similar Datasets

Project description:We identified a poor clinical response to treatment of cholera with a single 1 g dose of ciprofloxacin, a standard treatment for cholera.To determine reasons for the poor response and better therapeutic approaches we examined the minimal inhibitor concentration (MIC, n = 275) and disc-diffusion zone sizes (n = 205) for ciprofloxacin and nalidixic acid of V. cholerae O1 strains isolated in Bangladesh from 1994 to 2012, and reexamined data from 161 patients infected with Vibrio cholerae O1 recruited in four clinical trials who received single- or multiple-dose ciprofloxacin for treatment of cholera and compared their clinical response to the V. cholerae O1 susceptibility.Although all 275 isolates of V. cholerae O1 remained susceptible to ciprofloxacin using standard MIC and disc-diffusion thresholds, the MIC90 to ciprofloxacin increased from 0.010 in 1994 to 0.475 μgm/ml in 2012. Isolates became frankly resistant to nalidixic with the MIC90 increasing from 21 μgm/ml in 1994 to >256 μgm/ml and 166 of 205 isolates from 1994 to 2005 being frankly resistant using disc-diffusion testing. Isolates resistant to nalidixic acid by disc-diffusion testing had a median ciprofloxacin MIC of 0.190 μgm/ml (10th-90th centiles 0.022 to 0.380); nalidixic acid-susceptible isolates had a median ciprofloxacin MIC of 0.002 (0.002 to 0.012).The rate of clinical success with single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains was 94% (61 of 65 patients) and bacteriologic success 97% (63/65) compared to 18% (12/67) and 8% (5/67) respectively with nalidixic acid-resistant strains (P<0.001 for both comparisons). Multiple-dose treatment with ciprofloxacin had 86% and 100% clinical and bacteriologic success rates respectively in patients infected with nalidixic acid-susceptible strains of V. cholerae O1 compared to clinical success 67% and bacteriologic success 60% with nalidixic acid-resistant strains.Single-dose ciprofloxacin is not effective for treating cholera caused by V. cholerae O1 with diminished susceptibility to ciprofloxacin, and nalidixic acid disc-diffusion testing effectively screens for such isolates.

Dataset Information

Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.

Publications

Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets